Krystal Biotech, Inc. (KRYS)
Nasdaq: KRYS · Biological Products, (No Diagnostic Substances) · Pittsburgh, PA · filing with the SEC since 2017
Grade7.6
◀ Past 7.1● Present 9.0▶ Future 6.1
Income statement, as filed
In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2021 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
| Report filed | Feb 17, 2026 | Feb 19, 2025 | Feb 26, 2024 | Feb 27, 2023 | Feb 28, 2022 | Mar 1, 2021 | Mar 10, 2020 | Mar 12, 2019 | Mar 12, 2018 | · |
| Revenue | 389,130 | 290,515 | 50,699 | 0 | 0 | · | · | · | · | · |
| Research and development | 58,045 | 53,580r | 46,433r | 42,461 | 27,884 | 17,936 | 15,616 | 7,761 | 3,208 | 741 |
| Selling, general and administrative | 146,741 | 113,626r | 98,289r | 77,735 | · | · | · | · | · | · |
| General and administrative | · | · | 98,401 | 77,735 | 40,391 | 15,063 | 6,465 | 4,155 | 1,564 | 402 |
| Total operating expenses | 227,835 | 224,767r | 160,316r | 145,196 | 68,275 | 32,999 | 22,081 | 11,916 | 4,772 | 1,143 |
| Operating income | 161,295 | 65,748r | -109,617r | -145,196 | -68,275 | -32,999 | -22,081 | -11,916 | -4,772 | -1,143 |
| Interest expense | · | · | 0 | 0 | 1,492 | 0 | · | · | · | · |
| Interest income (expense), net | 28,176 | 29,608r | 22,514r | 5,221 | · | · | · | · | · | · |
| Total non-operating income (expense) | · | · | · | · | · | · | · | · | -3,148 | -7 |
| Income before income taxes | 189,471 | 95,356 | 12,897 | -139,975 | -69,570 | · | · | · | · | · |
| Income tax expense | -15,360 | 6,197 | 1,965 | 0 | 0 | 0 | 0 | 0 | 0 | · |
| Net income | 204,831 | 89,159 | 10,932 | -139,975 | -69,570 | -32,167 | -19,088 | -10,889 | -7,920 | -1,150 |
| Net income to common shareholders | · | · | · | · | · | · | · | · | -7,920 | -1,150 |
| Earnings per share, basic | 7.08 | 3.12 | 0.40 | -5.49 | -3.13 | -1.71 | · | · | · | · |
| Earnings per share, diluted | 6.84 | 3.00 | 0.39 | -5.49 | -3.13 | -1.71 | · | · | · | · |
| Earnings per share, basic and diluted | · | · | · | · | · | -1.71 | -1.20 | -0.97 | -1.48 | -1.31 |
| Weighted average shares, basic | 28,944,000 | 28,592,000 | 27,154,000r | 25,492,000r | 22,196,846 | 18,787,161 | · | · | · | · |
| Weighted average shares, diluted | 29,951,000 | 29,740,000 | 27,752,000r | 25,492,000r | 22,196,846 | 18,787,161 | · | · | · | · |
| Weighted average shares, basic and diluted | · | · | · | · | · | 18,787,161 | 15,901,083 | 11,203,081 | 5,360,536 | 877,490 |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Revenue what customers paid for what it sold
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTaxResearch and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseSelling, general and administrative the cost of selling and of running the company
us-gaap:SellingGeneralAndAdministrativeExpenseGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossInterest expense what its borrowing cost
us-gaap:InterestExpenseInterest income (expense), net interest earned less interest paid, outside the business
us-gaap:InterestIncomeExpenseNonoperatingNetTotal non-operating income (expense) everything outside the business, together
us-gaap:NonoperatingIncomeExpenseIncome before income taxes profit before tax
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestIncome tax expense tax charged on the period's profit
us-gaap:IncomeTaxExpenseBenefitNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossNet income to common shareholders what is left for common shareholders
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasicEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedEarnings per share, basic and diluted net income per share, where both counts are the same
us-gaap:EarningsPerShareBasicAndDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstandingWeighted average shares, basic and diluted the average count, where both counts are the same
us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted